# AlphaPARP

Source: https://onco.cc/drugs/alphaparp/  
OnCo record `alphaparp` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AlphaPARP is an experimental radioactive drug from Trevarx Biomedical that carries an alpha-emitting atom to the DNA-repair enzyme PARP1 in cancer cells. It is being prepared for a first trial in ovarian cancer.

## Summary

AlphaPARP ([211At]PTT) is Trevarx Biomedical's first therapeutic. The company states that its effect comes from DNA-proximal alpha energy deposition rather than from PARP inhibition itself. A 2026 National Cancer Institute SBIR award funds IND-enabling work for a phase 1 study in ovarian cancer, with a fluorine-18 companion imaging agent for patient selection. No registered trial was found.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-04
- Also known as: [211At]PTT; 211At-Parthanatine; Astatine-211 parthanatine
- Tags: pipeline
- Modality: Targeted alpha radiopharmaceutical (small molecule)
- Mechanism: Astatine-211 covalently attached to a PARP inhibitor analogue (Parthanatine) that binds activated PARP1 at sites of tumour DNA damage, so the alpha particle is emitted beside the DNA and causes double-strand breaks, as described by Trevarx Biomedical.

## Sources

- Trevarx Biomedical: https://www.trevarx.com/
- NIH RePORTER: award 1R44CA310342-01A1: https://reporter.nih.gov/project-details/11408032

## Connected records

- technologies: [Astatine-211 alpha therapy](https://onco.cc/technologies/astatine-211-alpha-therapy/), [Targeted alpha therapy](https://onco.cc/technologies/targeted-alpha-therapy/)
- targets: [PARP](https://onco.cc/targets/parp/)
- companies: [Trevarx Biomedical](https://onco.cc/companies/trevarx-biomedical/)

---
JSON: https://onco.cc/api/v1/entities/alphaparp.json